New combo aims to wipe out hidden myeloma after transplant

NCT ID NCT06107738

Recruiting now Disease control Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a combination of iberdomide (a pill) and daratumumab (an injection) can eliminate leftover cancer cells in multiple myeloma patients who still have minimal residual disease after a stem cell transplant. About 60 participants will receive up to 26 cycles of the two drugs. The main goal is to see how many become cancer-free at the molecular level after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iberdomide and daratumumab (injected under the skin)
What this could lead to: If successful, this combination could become a new maintenance option to keep multiple myeloma from returning after a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Side effects from the drugs could also limit their use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

KCI at McLaren Greater Lansing
RECRUITING

Lansing, Michigan, 48910, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.